Editorial Foreword - Milnacipran: recent findings in depression

Editorial Foreword - Milnacipran: recent findings in depression

Stuart Montgomery1, Mike Briley2 1Imperial College School of Medicine, London, England, UK; 2NeuroBiz Consulting and Communication, Castres, FranceMilnacipran: recent findings in depressionMilnacipran is a serotonin and norepinephrine reuptake inhibitor (SNRI) which was first approved for the treatm...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Stuart Montgomery, Mike Briley
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2010
Materias:
Neurosciences. Biological psychiatry. Neuropsychiatry
RC321-571
Neurology. Diseases of the nervous system
RC346-429
Acceso en línea:https://doaj.org/article/b865ead338664fdc9c611ed1c9f0f16d
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:b865ead338664fdc9c611ed1c9f0f16d
record_format dspace
spelling oai:doaj.org-article:b865ead338664fdc9c611ed1c9f0f16d2021-12-02T08:25:09ZEditorial Foreword - Milnacipran: recent findings in depression1176-63281178-2021https://doaj.org/article/b865ead338664fdc9c611ed1c9f0f16d2010-08-01T00:00:00Zhttp://www.dovepress.com/editorial-foreword---milnacipran-recent-findings-in-depression-a5108https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021Stuart Montgomery1, Mike Briley2 1Imperial College School of Medicine, London, England, UK; 2NeuroBiz Consulting and Communication, Castres, FranceMilnacipran: recent findings in depressionMilnacipran is a serotonin and norepinephrine reuptake inhibitor (SNRI) which was first approved for the treatment of major depressive episodes in France in December 1996. It is currently marketed for this indication (as Ixel®, Toledomin®, Tivanyl® or Dalcipran®) in over 45 countries worldwide including Japan. It was approved for the management of fibromyalgia in the US in 2009.This supplement, which is based on a symposium at the International Forum on Mood and Anxiety (IFMAD) held in Monaco in November 2009, highlights several recent clinical studies with milnacipran in depression. Stuart MontgomeryMike BrileyDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2010, Iss Supplement 1, Pp 1-2 (2010)
institution DOAJ
collection DOAJ
language EN
topic Neurosciences. Biological psychiatry. Neuropsychiatry
RC321-571
Neurology. Diseases of the nervous system
RC346-429
spellingShingle Neurosciences. Biological psychiatry. Neuropsychiatry
RC321-571
Neurology. Diseases of the nervous system
RC346-429
Stuart Montgomery
Mike Briley
Editorial Foreword - Milnacipran: recent findings in depression
description Stuart Montgomery1, Mike Briley2 1Imperial College School of Medicine, London, England, UK; 2NeuroBiz Consulting and Communication, Castres, FranceMilnacipran: recent findings in depressionMilnacipran is a serotonin and norepinephrine reuptake inhibitor (SNRI) which was first approved for the treatment of major depressive episodes in France in December 1996. It is currently marketed for this indication (as Ixel®, Toledomin®, Tivanyl® or Dalcipran®) in over 45 countries worldwide including Japan. It was approved for the management of fibromyalgia in the US in 2009.This supplement, which is based on a symposium at the International Forum on Mood and Anxiety (IFMAD) held in Monaco in November 2009, highlights several recent clinical studies with milnacipran in depression.
format article
author Stuart Montgomery
Mike Briley
author_facet Stuart Montgomery
Mike Briley
author_sort Stuart Montgomery
title Editorial Foreword - Milnacipran: recent findings in depression
title_short Editorial Foreword - Milnacipran: recent findings in depression
title_full Editorial Foreword - Milnacipran: recent findings in depression
title_fullStr Editorial Foreword - Milnacipran: recent findings in depression
title_full_unstemmed Editorial Foreword - Milnacipran: recent findings in depression
title_sort editorial foreword - milnacipran: recent findings in depression
publisher Dove Medical Press
publishDate 2010
url https://doaj.org/article/b865ead338664fdc9c611ed1c9f0f16d
work_keys_str_mv AT stuartmontgomery editorialforewordmilnacipranrecentfindingsindepression
AT mikebriley editorialforewordmilnacipranrecentfindingsindepression
_version_ 1718398563763879936

Ejemplares similares